In an era defined by uncertainty and increasing organizational complexity, the pressure on health and life science leaders to drive successful launches has reached a critical point. Traditional playbooks for bringing assets to market are being rewritten by technological shifts, shorter clinical-to-launch timelines, and a competitive landscape that moves faster than ever before. To explore what separates high-performing organizations from the rest, Remco op den Kelder, Global President of Inizio Ignite dives into leadership strategies that will define the next three to five years of the industry.
Key Objectives
Understand how continuous, real-time insights and evolving market dynamics require pharmaceutical leaders to shift from static launch planning to agile, adaptive execution models.
Evaluate strategies for integrating artificial intelligence into organizational workflows.
Identify approaches to breaking down silos between medical and commercial teams while maintaining compliance.
Hims & Hers partners with Eli Lilly to sell Zepbound and Foundayo directly on its platform, Novo Nordisk terminates its research collaboration with Korro Bio, and the FDA grants accelerated approval to Johnson & Johnson’s Rybrevant Faspro in head and neck cancer.
The agreement provides access for prescribed patients to Lilly's obesity medicines self-pay pricing starting at $149 per month without leaving the platform.
The termination ends a cardiometabolic RNA-editing partnership that was paused for 12 months, closing out a deal under which Korro earned no milestone payments.
Accelerated approval of subcutaneous Rybrevant Faspro (amivantamab) based on a 42% response rate in 102 patients; a phase 3 confirmatory trial is under way.
ANI Pharmaceuticals makes an offer to acquire Egetis Therapeutics as Egetis separately sells its priority review voucher for $190 million, Novartis exits its BrainTransporter deal with BioArctic 14 months after signing, and Ignite Proteomics’ Dr. Brian Corgiat on improving how tumors are tested after recurrence.